Literature DB >> 33058029

Derivation and Characterization of Mesenchymal Stem Cells from iPS Cells.

Qingguo Zhao1, Fei Liu2.   

Abstract

Mesenchymal stem/stromal cells (MSCs) show excellent therapeutic potentials in many preclinical studies and clinical trials. However, the clinical application of conventional tissue-derived MSCs faces challenges of limited scalability and high donor variations. To address these challenges, we established a protocol for deriving and characterizing MSCs from human induced pluripotent stem cells (iPSCs) with a theoretically limitless expandability. The iPSC-MSCs show biological properties comparable to or better than early passage bone marrow MSCs and can be scaled up to huge amounts with uniform properties.
© 2020. Springer Science+Business Media New York.

Entities:  

Keywords:  Characterization; Derivation; Induced pluripotent stem cells; Mesenchymal stem/stromal cells; Scalability

Mesh:

Year:  2022        PMID: 33058029     DOI: 10.1007/7651_2020_327

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  16 in total

1.  Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells.

Authors:  Benjamin L Larson; Joni Ylostalo; Ryang H Lee; Carl Gregory; Darwin J Prockop
Journal:  Tissue Eng Part A       Date:  2010-07-13       Impact factor: 3.845

Review 2.  Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.

Authors:  Jacques Galipeau; Luc Sensébé
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

3.  Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation.

Authors:  Sowmya Viswanathan; Armand Keating; Robert Deans; Peiman Hematti; Darwin Prockop; David F Stroncek; Glyn Stacey; Dan J Weiss; Christopher Mason; Mahendra S Rao
Journal:  Stem Cells Dev       Date:  2014-03-10       Impact factor: 3.272

Review 4.  Isolation, cultivation, and characterization of human mesenchymal stem cells.

Authors:  Dolly Mushahary; Andreas Spittler; Cornelia Kasper; Viktoria Weber; Verena Charwat
Journal:  Cytometry A       Date:  2017-10-26       Impact factor: 4.355

5.  Comparison of the anti-inflammatory effects of induced pluripotent stem cell-derived and bone marrow-derived mesenchymal stromal cells in a murine model of corneal injury.

Authors:  Young In Yun; Se Yeon Park; Hyun Ju Lee; Jung Hwa Ko; Mee Kum Kim; Won Ryang Wee; Roxanne L Reger; Carl A Gregory; Hosoon Choi; Samuel F Fulcher; Darwin J Prockop; Joo Youn Oh
Journal:  Cytotherapy       Date:  2016-11-10       Impact factor: 5.414

6.  Global proteomic signature of undifferentiated human bone marrow stromal cells: evidence for donor-to-donor proteome heterogeneity.

Authors:  Samuel T Mindaye; Moonjin Ra; Jessica L Lo Surdo; Steven R Bauer; Michail A Alterman
Journal:  Stem Cell Res       Date:  2013-06-02       Impact factor: 2.020

7.  MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs.

Authors:  Qingguo Zhao; Carl A Gregory; Ryang Hwa Lee; Roxanne L Reger; Lizheng Qin; Bo Hai; Min Sung Park; Nara Yoon; Bret Clough; Eoin McNeill; Darwin J Prockop; Fei Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

8.  Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering.

Authors:  Ramakrishnaiah Siddappa; Ruud Licht; Clemens van Blitterswijk; Jan de Boer
Journal:  J Orthop Res       Date:  2007-08       Impact factor: 3.494

9.  Biomimetic nanovesicles made from iPS cell-derived mesenchymal stem cells for targeted therapy of triple-negative breast cancer.

Authors:  Qingguo Zhao; Bo Hai; Xiao Zhang; Jing Xu; Brian Koehler; Fei Liu
Journal:  Nanomedicine       Date:  2019-12-27       Impact factor: 5.307

10.  Inhibitory Effects of iPSC-MSCs and Their Extracellular Vesicles on the Onset of Sialadenitis in a Mouse Model of Sjögren's Syndrome.

Authors:  Bo Hai; Taeko Shigemoto-Kuroda; Qingguo Zhao; Ryang Hwa Lee; Fei Liu
Journal:  Stem Cells Int       Date:  2018-03-15       Impact factor: 5.443

View more
  1 in total

1.  Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial.

Authors:  Chunxue Wang; Dongyang Zhao; Liang Zheng; Xiaowei Bao; Qian Yang; Sen Jiang; Xiaohui Zhou; Lunxian Tang; Zhongmin Liu
Journal:  BMJ Open       Date:  2022-04-04       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.